Abstract
The heterogeneity of myelodysplastic syndromes (MDS) has made evaluating patient response to treatment challenging. In 2006, an International Working Group (IWG) proposed a revision to previously published standardized response criteria (IWG 2000) for uniformly evaluating clinical responses in MDS. These IWG 2006 criteria have been used prospectively in many clinical trials in MDS, but proved challenging in several of them, especially for the evaluation of erythroid response. In this report, we provide rationale for modifications (IWG 2018) of these recommendations, mainly for “hematological improvement” criteria used for lower risk MDS, based on recent practical and reported experience in clinical trials. Most suggestions relate to erythroid response assessment, which are refined in an overall more stringent manner. Two major proposed changes are the differentiation between “procedures” and "criteria" for hematologic improvement-erythroid (HI-E) assessment and a new categorization of transfusion burden subgroups.
- Submitted June 8, 2018.
- Accepted October 29, 2018.
- Copyright © 2018 American Society of Hematology
To view this item, select one of the options below.
ASH Members and Subscribers
If you already have a subscription, you may gain access using your ASH username and password.
Purchase Short-Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$75.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
OpenAthens Users
Log in through your institution
Sign Up
Subscribe to the Journal - Subscribe to the print and/or online journal.
Access for Patients
